Hyperbaric Oxygen Therapy as a Sole Agent Is Not Immunosuppressant in a Highly Immunogenic Mouse Model

Adam Gassas,Susan Carter,Eyal Grunebaum,George K Sándor,A Wayne Evans,Weixian Min

doi:10.1155/2011/579268

Adam Gassas, Susan Carter + Show 4 more

Open Access

https://doi.org/10.1155/2011/579268

Copy DOI

Abstract

Background. Hyperbaric oxygen (HBO) therapy, which is used for many conditions, may also have immunosuppressive effects and could be used for prevention or treatment of graft-versus-host disease (GvHD). If HBO is immunosuppressant, then we hypothesize that HBO therapy will delay the T-cell mediated skin graft rejection. Methods. C57/BL6 black-coated (H2B) mice received skin graft from CBA (H2D) white-coated mice. Mice were treated with either 19 session of 240 kpa oxygen or 29 session of 300 kpa oxygen, for 90 minutes. Mice were housed either 4 per cage or separately, to prevent friction and mechanical factors that may affect graft survival. Skin grafts were assessed daily. Results. There was no difference in length of graft survival between mice that received either regimens of HBO therapy and mice that did not receive HBO therapy. Conclusions. HBO therapy, as a sole agent, did not delay skin graft rejection in a highly immunogenic mouse model.

Highlights

Exposure to Hyperbaric oxygen (HBO) therapy, at least in rodents, appears to be immunosuppressant and leads to an anti-inflammatory effect
In this study we found that HBO therapy as a sole agent was not immunosuppressant enough to cause delay in allo-skin graft rejection
In 1979, Jacobs et al reported that a mouse ear composite allograft rejection was significantly delayed by exposure to HBO therapy [20]

Summary

Introduction

Exposure to HBO therapy, at least in rodents, appears to be immunosuppressant and leads to an anti-inflammatory effect. HBO exposure attenuates the immune system, increases the susceptibility to respiratory infections [5, 6], and delays allograft rejection in mice [7,8,9]. Our aim was to test the effect of HBO therapy on the immune system by measuring the integrity and the duration of skin allogeneic graft in mice. Graft rejection is a T-cell mediated phenomenon, and if HBO therapy is immunosuppressant, Bone Marrow Research exposure to HBO therapy could potentially delay graft rejection. Hyperbaric oxygen (HBO) therapy, which is used for many conditions, may have immunosuppressive effects and could be used for prevention or treatment of graft-versus-host disease (GvHD). If HBO is immunosuppressant, we hypothesize that HBO therapy will delay the T-cell mediated skin graft rejection. HBO therapy, as a sole agent, did not delay skin graft rejection in a highly immunogenic mouse model

Objectives

Methods

Results

Conclusion